Puesta al día para el médico práctico | 28 JUL 19

Arteritis de células gigantes

Actualización para la práctica de no especialistas, particularmente del diagnóstico y el tratamiento inicial
14
19
Autor: Karina Lazarewicz , Pippa Watson.  BMJ 2019;365:l1964.
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

 

1 Barraclough K, Mallen CD, Helliwell T, Hider SL, Dasgupta B. Diagnosis and management of giant cell arteritis. Br J Gen Prac 2012 62; 329-30.

2 National Institute for Health and Care Excellence. Giant cell arteritis, Clinical Knowledge Summaries. 2014. https://cks.nice.org.uk/giant-cell-arteritis

3 Dasgupta B, Borg FA, Hassan N, etal. BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford) 2010;49:1594-7. 10.1093/rheumatology/keq039a 20371504

4 Ness T, Bley TA, Schmidt WA, Lamprecht P. The diagnosis and treatment of giant cell arteritis. Dtsch Arztebl Int 2013;110:376-85, quiz 386.23795218

5 Cid MC, Campo E, Ercilla G, et al. Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis. Influence of corticosteroid treatment. Arthritis Rheum 1989;32:884-93.2787641

6 González-Gay MA, Blanco R, Rodríguez-Valverde V, etal . Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998;41:1497-504.

10.1002/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z 9704651

7 Fraser JA, Weyand CM, Newman NJ, Biousse V. The treatment of giant cell arteritis. Rev Neurol Dis 2008;5:140-52.18838954

8 González-Gay MA, Barros S, Lopez-Diaz MJ, Garcia-Porrua C, Sanchez-Andrade A, Llorca J. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) 2005;84:269-76.

10.1097/01.md.0000180042.42156.d1 16148727

9 Royal College of Physicians. Diagnosis and management of giant cell arteritis. 2010. https://www.rcplondon.ac.uk/guidelines-policy/diagnosis-and-management-giant-cellarteritis 10 Hayreh SS. Masticatory muscle pain: an important indicator of giant cell arteritis. Spec Care Dentist 1998;18:60-5. 10.1111/j.1754-4505.1998.tb00905.x 9680912

11 Kumarasinghe AP, Hepburn A, Reuther WJ, Pratt C. Temporal arteritis presenting with tongue necrosis. BMJ Case Rep 2012;2012:bcr2012007241. 10.1136/bcr-2012-007241 23166175

12 Hassan N, Dasgupta B, Barraclough K. Giant cell arteritis. BMJ 2011;342:d3019. 10.1136/bmj.d3019 21606138

13 Rana AQ, Saeed U, Khan OA, Qureshi AR, Paul D. Giant cell arteritis or tension-type headache?: A differential diagnostic dilemma. J Neurosci Rural Pract 2014;5:409-11. 10.4103/0976-3147.140005 25288850

14 Nishino H, DeRemee RA, Rubino FA, Parisi JE. Wegener’s granulomatosis associated with vasculitis of the temporal artery: report of five cases. Mayo Clin Proc 1993;68:115-21.10.1016/S0025-6196(12)60157-8 8423690

15 Hunder GG, Bloch DA, Michel BA, etal . The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8. 10.1002/art.1780330810 2202311

16 Davies CG, May DJ. The role of temporal artery biopsies in giant cell arteritis. Ann R Coll Surg Engl 2011;93:4-5. 10.1308/003588411X12851639107476 21418754

17 Monti S, Floris A, Ponte CB, etal . The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice. Rheumatology (Oxford) 2018;57:112-9. 10.1093/rheumatology/kex341 29045738

18 Chevalet P, Barrier JH, Pottier P, etal . A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 2000;27:1484-91.10852275

19 Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004;50:1332-7. 10.1002/art.20171 15077317

20 Alba MA, García-Martínez A, Prieto-González S, etal . Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore) 2014;93:194-201. 10.1097/MD.0000000000000033 25181312

21 Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 2002;80:355-67. 10.1034/j.1600-0420.2002.800403.x 12190776

22 Nuenninghoff DM, Hunder GG, Christianson TJH, McClelland RL, Matteson EL. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003;48:3522-31. 10.1002/art.11353 14674004

23 Villiger PM, Adler S, Kuchen S, etal . Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016;387:1921-7. 10.1016/S0140-6736(16)00560-2 26952547

24 Stone JH, Tuckwell K, Dimonaco S, etal . Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017;377:317-28. 10.1056/NEJMoa1613849 28745999

25 Bert RJ, Antonacci VP, Berman L, Melhem ER. Polyarteritis nodosa presenting as temporal arteritis in a 9-year-old child. AJNR Am J Neuroradiol 1999;20:167-71.9974076 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions

 

Comentarios

Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí

 
Contenidos relacionados
Los editores le recomiendan continuar con las siguientes lecturas: